Printed from the IBC Life Sciences Web site on May 21, 2012 6:05 AM ET.
Page location: http://www.ibclifesciences.com/TIDES/overview.xml
May 20-23, 2012 · Mandalay Bay Resort & Casino · Las Vegas, NV
Recently, we asked the world-class TIDES speaker faculty to share some interesting facts about themselves that not too many people know. We compiled the 10 most fascinating responses below. We find them pretty amusing and hope you will too.
Looking for the answers?
» Find them on the answers page
Therapeutic Oligonucleotide Development: A Promising Outlook
Arthur M. Krieg, M.D., President and Chief Executive Officer, RaNA Therapeutics, Inc.
Resources to Enable and Facilitate siRNA Drug Development in China
Zicai Liang, Ph.D., Chairman, Suzhou Ribo Life Science Co., LTD, China
Harnessing the "New" Endocrinology of Peptide Hormones - Discovery of Novel Therapies Targeting Metabolic Disease
David E. Moller, M.D., Vice President, Endocrine and Cardiovascular Research and Clinical Investigation, Lilly Research Laboratories, Eli Lilly and Co.
RaPID Discovery of Natural Product-Like Peptides against Therapeutic Targets
Hiroaki Suga, Ph.D., Professor, Chemical Biology and Biotechnology Lab, The University of Tokyo, Japan
The Next Generation in Clinical Molecular Diagnostics
Trevor Hawkins, Ph.D., CEO, Next Generation Diagnostics, Siemens Healthcare Diagnostics
Update on Commercialization of RUO and IUO Products and Oversight of Lab-Developed Tests
Sam Rua, VP, Regulatory Affairs and Quality Systems, HTG Molecular Diagnostics, Inc.
Special Discounted Hotel Rate Available Until April 3, 2012.
To book your room, call 702-632-9000 and reference IBC or TIDES.
Join our priority contact list and receive the latest event news.
Case Studies on CMC Challenges, Early Drug Product Development and Delivery Alternatives
Plan for the future as you enjoy a dynamic keynote session including:
Improving Drug-Like Properties to Accelerate Preclinical and Clinical Development
Exploiting Peptides as Intracellular Drugs, Novel Scaffolds and Improved Molecules for Therapeutic Development
Accelerating Product Development through Cutting Edge Regulatory, Business and Technology Strategies
"TIDES is an excellent opportunity to gain knowledge into the vastly expanding area of peptides and oligonucletides. Furthermore, it gives attendees an invaluable chance for networking and building relationships with other experts in the field." -Barry P. O'Connor, Ph.D., Research Scientist, R&D, Sekisui Medical Co., LTD., Japan
"I've looked over the entire agenda and the TIDES 2012 seems like it will be one of the best, if not THE best, meeting I'll attend in 2012." - Richard A. Montagna, Ph.D., Senior Vice President for Corporate Business Development & Scientific Affairs, Rheonix, Inc.
"I have never heard so many good lectures in so little time. Excellent program! Would go again next year." - Peter Timmerman, Chief Technology Officer, Pepscan Therapeutics
"TIDES 2011 was a very productive conference. I had lots of good meetings, with many types of companies. The marriage of the conferences on discovery and manufacturing will make this event a must be for people interested in the TIDES, particularly the oligonucleoTIDES field." - Sven Klussmann, Ph.D., Chief Scientific Officer, NOXXON Pharma AG, Germany
"The TIDES 2011 Conference was a very well organised event. I enjoyed the conference and found it a very good networking platform with vendors and other attendees from various pharmaceutical companies. I shared my latest data in a poster presentation which sparked off some interesting conversations, and I will be applying my learning's from the conference in my day to day investigations." - Nainesh Patel, Senior Scientist, GlaxoSmithKline, UK
"TIDES is an excellent meeting to catch up on the latest efforts in industry on peptide therapeutics and technologies." - Suresh M. Pitram, Senior Research Investigator, Integrated Diagnostics
"Excellent oligonucleotide chemistry, discovery and optimization…" - Steve Shrewsbury, Chief Medical Officer, AVI Biopharma